Information Provided By: 
Fly News Breaks for June 29, 2016
TSRO
Jun 29, 2016 | 11:08 EDT
Wedbush analyst David Nierengarten raised his price target for TESARO to $92 after niraparib met all cohorts in today's trial results. The analyst expects niraparib "will be approved as first-in-class in the large HRD+ ovarian market, with superior efficacy data compared to other PARP inhibitors." The NOVA trial bodes well for other studies of niraparib, and significantly raises the likelihood of TESARO becoming an acquisition candidate, Nierengarten tells investors in a research note. He reiterates an Outperform rating on the shares.
News For TSRO From the Last 2 Days
There are no results for your query TSRO
